Patent Law Weblog
recent posts
- Argentina Repeals Pharmaceutical Patent Examination Guidelines
- USPTO Moves to Protect Design Rights for Digital Innovations
- Judicial Conduct and Disability Committee Has Its Say, Denies Judge Newman’s Latest Request for Review
- PTAB Issues Judgment on Priority in CRISPR Interference
- Parties File Supplemental Priority Statements in CRISPR Interference
about
Category: Patent Legislation
-
By Kevin E. Noonan — A prominent Israeli commentator has added his voice to the growing chorus of objections to the patent "reform" bill under consideration by the Senate (S. 1145). In an opinion piece published by the Jerusalem Post on Wednesday, Bernard Frieder, a technology specialist with experience consulting on intellectual property…
-
By Kevin E. Noonan — Judge Paul Michel (at right), Chief Judge of the Court of Appeals for the Federal Circuit, recently had the opportunity to speak to a meeting of the Association of Corporate Patent Counsel, one of the preeminent patent law groups in the country and one of the most exclusive…
-
By Kevin E. Noonan — In discussing the patent "reform" bill waiting to be brought to the floor for a vote in the Senate (S. 1145), various stakeholders have availed themselves of their right to petition the government for redress in opposition to the bill, and Patent Docs has published, supported, and encouraged…
-
By Kevin E. Noonan — Earlier today, Patent Docs participated in a conference call with Jim Greenwood (at right), the President and CEO of the Biotechnology Industry Organization (BIO). Mr. Greenwood, who represented Pennsylvania’s Eighth District in the U.S. House of Representatives from January 1993 through January 2005 prior to his BIO appointment,…
-
By Kevin E. Noonan — The Biotechnology Industry Organization (BIO) earlier this week released a report on the purported bases of current patent "reform" efforts that have culminated in passage of a bill in the House of Representatives (H.R. 1908) and consideration of another bill by the Senate (S. 1145). The Senate bill…
-
By Donald Zuhn — A report on Forbes.com indicates that Millennium Pharmaceuticals spent $1.28 million last year lobbying Congress and the Department of Commerce on patent reform and biologics legislation. According to the report, Millennium disclosed its lobbying tab for the second half of the year in a filing with the Senate public…
-
By Michael A. Einhorn, Ph.D. — [Ed. – Dr. Einhorn (at right) is an Academic Affiliate of Campos and Stratis IP and an Adjunct Professor at the Rothman Institute of Entrepreneurship at Fairleigh Dickinson University in Madison, New Jersey. The following article originally appeared in the Intellectual Property Newsletter of the American Bar…
-
By Donald Zuhn — The U.S. Patent and Trademark Office announced today that Nathaniel Wienecke (at right), Assistant Secretary for Legislative and Intergovernmental Affairs of the U.S. Department of Commerce, has addressed a letter to Senator Patrick Leahy, Chairman of the Senate Judiciary Committee, expressing the Bush Administration’s views on the Senate patent…
-
By Donald Zuhn –- Last week, we reported on nine letters that were sent to the Senators of eight states between December 12, 2007 and January 29, 2008 by a collection of universities, businesses, and organizations. In the letters, the signatories contend that the Senate’s patent reform bill will harm innovation and result…
-
By Kevin E. Noonan — The rising tide has now become a flood of U.S. universities, businesses, and individuals in opposition to the patent "reform" bill poised for a vote in the Senate (S. 1145). And the mechanism for this opposition is the traditional way Americans petition their government for redress — the…
Patent Docs 